Eli Lilly
OncoDNA, Eli Lilly Partner on Thyroid Cancer Biomarker Testing
The companies are working together to offer next-generation sequencing-based molecular testing on thyroid cancer biopsies to clinicians in Italy.
Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers
The NGS-based Oncomine Dx Target Test will help ID patients with advanced RET-driven lung and thyroid cancers who may be eligible for treatment with Eli Lilly's Retevmo.
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.
NeoGenomics, Eli Lilly to Offer Molecular Testing to Non-Small Cell Lung Cancer Patients
Patients will have the opportunity to be tested with NeoGenomics' next-generation sequencing-based NeoType DNA and RNA Assay at no cost.
Foundation Medicine, Eli Lilly Ink CDx Development Deal for Retevmo
The collaboration will initially explore the use of FoundationOne CDx for patients with metastatic rearranged transfection fusion across tumor types.